Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - NASDAQ fell 0.03% to 22,341.05, and S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - Adjusted earnings for Dave & Buster's were 40 cents per share, below estimates of 92 cents per share [2] Commodities - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell 0.1% to $4.7120 [5] European Markets - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, and London's FTSE 100 fell 0.74% [6] Asian Markets - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - The NASDAQ fell 0.03% to 22,341.05, and the S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - The company reported adjusted earnings of 40 cents per share, falling short of estimates of 92 cents per share [2] Commodity Market - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell by 0.1% to $4.7120 [5] European Market - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, London's FTSE 100 fell 0.74%, Germany's DAX 40 dipped 1.29%, and France's CAC 40 fell 0.72% [6] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

Core Viewpoint - Bionano Genomics, Inc. has announced a public offering of 5,000,000 shares of common stock and associated Series E and Series F warrants, aiming to raise approximately $10 million before expenses, with potential additional proceeds of about $20 million if the warrants are fully exercised [1][3]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with Series E warrants expiring in five years and Series F warrants expiring in eighteen months [1]. - The offering is expected to close on or about September 17, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $10 million before deducting fees and expenses [3]. - If fully exercised, the Series Warrants could provide an additional gross proceeds of approximately $20 million [3]. - The net proceeds will be used for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions, diagnostic services, and software, with a mission to transform genome analysis [6]. - Bionano also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology [6].

Core Insights - Bionano Genomics has published a book series focusing on chromoanagenesis, emphasizing the advantages of optical genome mapping (OGM) in this area of research [1][4] - Chromoanagenesis is linked to complex karyotypes and poor prognosis in cancers, making its detection crucial for understanding disease biology [2][4] - OGM offers high-resolution genome-wide views of structural variants, facilitating the identification of genomic variations associated with chromoanagenesis [2][4] Company Overview - Bionano Genomics specializes in genome analysis solutions, aiming to transform genomic insights through OGM technology and related services [5] - The company provides OGM solutions applicable in various research fields, including basic, translational, and clinical research [5] - Bionano also offers diagnostic testing services through its subsidiary, Lineagen, Inc., which utilizes OGM technology [5] Research Developments - The initial study utilizing OGM for chromoanagenesis was published in January 2025, focusing on acute myelogenous leukemia (AML) [3] - The book series includes studies expanding OGM applications to other cancers like multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) [3] - New methodologies, such as dam-assisted fluorescent tagging of chromatin accessibility, are being developed for detailed analysis of chromatin structures [3]

Core Insights - Bionano Laboratories announced a preliminary payment determination from CMS for a new CPT code for optical genome mapping (OGM) in detecting genetic disorders, priced at $1263.53, which is higher than existing microarray codes [1][2][3] Group 1: CPT Code and Pricing - The new Category I CPT code for OGM will facilitate reimbursement for laboratory developed tests (LDTs) based on OGM, providing a pricing advantage over traditional methods [2][3] - The new CPT code 81354 for constitutional genetic disease analysis is expected to be priced at $1263.53, which is $363.53 higher than code 81228 and $103.53 higher than code 81229 [1][2] Group 2: Clinical Applications and Impact - OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV are expected to be covered under the new CPT code, indicating their relevance in clinical settings [2][3] - The introduction of this CPT code is anticipated to enhance awareness and support for OGM in both oncology and clinical genetic testing communities globally [3] Group 3: Company Overview - Bionano Laboratories, a subsidiary of Bionano Genomics, specializes in CLIA-certified LDTs utilizing OGM technology to advance genetic diagnostics [4][5] - The company aims to transform genome analysis through innovative solutions and diagnostic services, including OGM and related software [5]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 921 ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" approach, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Fast-moving trending stocks can be difficult to enter at the right time, as they may lose momentum if future growth does not justify their high valuations [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: Bionano Genomics, Inc. (BNGO) Analysis - BNGO has shown a four-week price change of 37.1%, indicating strong recent price momentum and growing investor interest [4] - Over the past 12 weeks, BNGO's stock gained 9.3%, with a beta of 2.25, suggesting it moves 125% higher than the market in either direction [5] - BNGO has a Momentum Score of A, indicating a favorable time to invest based on momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to BNGO earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - BNGO is trading at a Price-to-Sales ratio of 0.68, suggesting it is undervalued, as investors pay only 68 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides BNGO, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies to help identify potential winning stocks based on various investing styles [9]

Summary of Bionano Genomics FY Conference Call Company Overview - **Company**: Bionano Genomics (NasdaqCM: BNGO) - **Industry**: Biotechnology, specifically focusing on digital pathology and optical genome mapping Key Points and Arguments 1. **Transformation and Market Position**: Bionano Genomics has undergone a significant transformation over the past year, focusing on digitizing pathology processes and positioning itself as a digital pathology company [2][4] 2. **Market Opportunity**: The company estimates an available market of approximately $10 billion, consisting of around 10,000 labs processing about 10 million cases annually [4] 3. **Challenges with Traditional Methods**: Traditional cytogenetic methods like karyotyping are outdated, labor-intensive, and often yield limited clinical utility, with only about 50% providing useful information for therapy guidance [5][6] 4. **Optical Genome Mapping (OGM)**: OGM offers a faster, simpler workflow that consolidates multiple traditional methods into one, consistently finding more actionable variants compared to karyotyping [7][8] 5. **CPT Codes**: The establishment of Category 1 CPT codes by the American Medical Association for OGM in hematologic malignancies and constitutional genetic disorders enhances reimbursement prospects and adoption [8][9][21] 6. **Complementary Technology**: OGM is not in competition with sequencing but is complementary, allowing labs to run both technologies side by side for improved results [9][13] 7. **Product Portfolio**: The company offers a broad product portfolio, including the Stratus and Saphyr instruments, the Ionic Purification System, and VIA software, which enhances workflow efficiency [10][11][12] 8. **Focus on Routine Use Customers**: The strategy has shifted towards supporting existing customers who consistently purchase consumables, aiming to increase their utilization and profitability [17][18] 9. **Revenue Growth**: In 2025, the company reported mid-double-digit growth in consumables and software revenue from existing customers, with expectations for continued acceleration [19][20] 10. **Cost Structure Improvements**: Bionano Genomics has significantly reduced its operating costs and improved gross margins, achieving 52% in the second quarter of 2025 [22][23] 11. **Future Guidance**: The company has reiterated its annual revenue guidance of $26 million to $30 million and raised its guidance for new system installations from 15-20 to 20-25 [24] Additional Important Content - **Publications as Growth Indicators**: A record number of publications in the second quarter of 2025 indicates strong product usage and potential for attracting new customers [20][21] - **Geographic Focus**: Key markets include the United States, Canada, Western Europe, and Israel, where OGM has a strong foothold [5][14] - **Application Areas**: The primary application areas for OGM include hematologic malignancies, constitutional genetic diseases, and cell and gene therapy [14][16] This summary encapsulates the critical insights from the Bionano Genomics FY Conference Call, highlighting the company's strategic direction, market opportunities, and financial performance.

Company Overview - Bionano Genomics, Inc. is a provider of genome analysis solutions aimed at addressing complex questions in biology and medicine [3] - The company's mission is to transform genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] Upcoming Conference - Erik Holmlin, PhD, the CEO of Bionano, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - The presentation is scheduled from 3:00 p.m. to 3:30 p.m. ET [2] - A recording of the session will be available on the Bionano website for at least 30 days following the conference [2]